Long-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry

被引:0
|
作者
Sack, Coralynn [1 ]
Wojdyla, Daniel M. [2 ]
Macmurdo, Maeve G. [3 ]
Gassett, Amanda [1 ]
Kaufman, Joel D. [1 ]
Raghu, Ganesh [1 ]
Redlich, Carrie A. [4 ]
Li, Peide [5 ]
Olson, Amy L. [5 ]
Leonard, Thomas B. [5 ]
Todd, Jamie L. [2 ,6 ]
Neely, Megan L. [2 ,6 ]
Snyder, Laurie D. [2 ,6 ]
Gulati, Mridu [4 ]
机构
[1] Univ Washington, 303 Roosevelt One Bldg,4225 Roosevelt Way NE, Seattle, WA 98105 USA
[2] Duke Clin Res Inst, Durham, NC USA
[3] Cleveland Clin, Cleveland, OH USA
[4] Yale Sch Med, New Haven, CT USA
[5] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[6] Duke Univ, Med Ctr, Durham, NC USA
关键词
interstitial lung diseases; pulmonary fibrosis; pollution; ACUTE EXACERBATION; ASSOCIATION; DIAGNOSIS; SURVIVAL;
D O I
10.1513/AnnalsATS.202404-382OC
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Rationale: Although exposure to air pollution is a known risk factor for adverse pulmonary outcomes, its impact in individuals with idiopathic pulmonary fibrosis (IPF) is less well understood. Objectives: To investigate the effects of long-term exposure to air pollution on disease severity and progression in patients with IPF and to determine whether genomic factors, such as MUC5B promoter polymorphism or telomere length, modify these associations. Methods: We performed analyses at enrollment and after 1 year of follow-up in the IPF-PRO (Idiopathic Pulmonary Fibrosis Prospective Outcomes) Registry, a prospective observational registry that enrolled individuals with IPF at 46 U.S. sites from June 2014 to October 2018. Five-year average pollution exposures (particulate matter <= 2.5 mu m in aerodynamic diameter [PM2.5], nitrogen dioxide, ozone) before the enrollment date were estimated at participants' residential addresses with validated national spatiotemporal models. Multivariable regression models estimated associations between pollution exposure and physiologic measurements (forced vital capacity [FVC], diffusing capacity of the lung for carbon monoxide, supplemental oxygen use at rest) and quality-of-life measurements (St. George's Respiratory Questionnaire, EuroQoL, Cough and Sputum Assessment Questionnaire) at enrollment. Cox proportional hazards models estimated associations between pollutants and a composite outcome of death, lung transplant, or >10% absolute decline in FVC percent predicted in the year after enrollment. Models were adjusted for individual-level and spatial confounders, including proxies for disease onset. Gene-environment interactions with MUC5B and telomere length were assessed. Results: Of 835 participants, 94% were non-Hispanic White individuals, 76% were male, and the mean (standard deviation) age was 70 (7.7) years. In fully adjusted analyses, higher PM2.5 exposure was associated with worse quality of life per St. George's Respiratory Questionnaire activity score (3.48 [95% confidence interval (CI), 0.64, 6.32] per 2 mu g/m(3) PM2.5) and EuroQoL scores (-0.04 [95% CI, -0.06, -0.01] per 2 mu g/m(3) PM2.5), as well as lower FVC percent predicted and lower diffusing capacity of the lung for carbon monoxide percent predicted at enrollment(.) Each 3 parts per billion difference in O-3 exposure was associated with a 1.57% (95% CI, 0.15, 2.98) higher FVC percent predicted at enrollment, although this effect was attenuated in multipollutant models. There was no association between nitrogen dioxide and enrollment measures or between pollution exposure and 1-year outcomes and no evidence for gene-environment interactions. Conclusions: In the IPF-PRO Registry, long-term exposure to PM2.5 was associated with worse quality of life and lung function at enrollment, but not with short-term disease progression or mortality. There was no evidence of effect modification by interaction of genomic factors with pollution. The reason for the unexpected relationship between O-3 exposure and higher FVC is unclear.
引用
收藏
页码:378 / 386
页数:9
相关论文
共 50 条
  • [21] Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis Data from the IPF-PRO Registry
    Salisbury, Margaret L.
    Conoscenti, Craig S.
    Culver, Daniel A.
    Yow, Eric
    Neely, Megan L.
    Bender, Shaun
    Hartmann, Nadine
    Palmer, Scott M.
    Leonard, Thomas B.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2020, 17 (11) : 1413 - 1423
  • [22] DISEASE SEVERITY AND QUALITY OF LIFE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF): AN ANALYSIS OF THE IPF-PRO REGISTRY
    O'Brien, Emily
    Hellkamp, Anne
    Neely, Megan
    Swaminathan, Aparna
    Bender, Shaun
    Snyder, Laurie
    Culver, Daniel
    Conoscenti, Craig
    Todd, Jamie
    Palmer, Scott
    Leonard, Thomas
    CHEST, 2019, 156 (04) : 1580A - 1581A
  • [23] Characteristics of Patients with Idiopathic Pulmonary Fibrosis Admitted to Hospital: Data from the IPF-PRO Registry
    Strek, M. E.
    Snyder, L. D.
    Adegunsoye, A.
    Neely, M. L.
    Bender, S.
    White, E. S.
    Conoscenti, C. S.
    Kim, H. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [24] Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry
    Fan, Yanni
    Bender, Shaun D.
    Conoscenti, Craig S.
    Davidson-Ray, Linda
    Cowper, Patricia A.
    Palmer, Scott M.
    de Andrade, Joao A.
    CHEST, 2020, 157 (06) : 1522 - 1530
  • [25] Newly Diagnosed IPF at Tertiary Care Pulmonary Centers: Initial Results From the Idiopathic Pulmonary Fibrosis - PROspective Outcomes (IPF-PRO) Registry
    Durheim, Michael
    O'Brien, Emily
    Gamerman, Victoria
    Todd, Jamie
    Snyder, Laurie
    Anstrom, Kevin
    Palmer, Scott
    Conoscenti, Craig
    CHEST, 2015, 148 (04)
  • [26] Association of Circulating Metabolites With Disease Severity and Mortality in Patients With Idiopathic Pulmonary Fibrosis: Data From the IPF-PRO Registry
    Summer, R. S.
    Todd, J. L.
    Neely, M. L.
    Lobo, L.
    Namen, A. M.
    Newby, L.
    Shafazand, S.
    Suliman, S.
    Hesslinger, C.
    Keller, S.
    Leonard, T. B.
    Palmer, S. M.
    Ilkayeva, O.
    Muehlbauer, M. J.
    Newgard, C. B.
    Roman, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [27] Predictors of death or transplant in patients with idiopathic pulmonary fibrosis in the IPF-PRO Registry
    Snyder, Laurie
    Neely, Megan L.
    Hellkamp, Anne
    O'Brien, Emily
    Flaherty, Kevin R.
    De Andrade, Joao
    Conoscenti, Craig
    Leonard, Thomas
    Bender, Shaun
    Gulati, Mridu
    Culver, Daniel A.
    Kaner, Robert J.
    Palmer, Scott
    Kim, Hyun J.
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [28] Effect of Antifibrotic Therapy on Survival in Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry
    De Andrade, J. A.
    Neely, M. L.
    Hellkamp, A. S.
    Culver, D. A.
    Kim, H. J.
    Liesching, T.
    Lobo, L. J.
    Ramaswamy, M.
    Safdar, Z.
    Bender, S.
    Conoscenti, C. S.
    Palmer, S. M.
    Snyder, L. D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [29] Disparities in Lung Transplantation Among Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry
    Swaminathan, A.
    Hellkamp, A. S.
    Neely, M. L.
    Bender, S.
    Luca, P.
    White, E. S.
    Palmer, S. M.
    Whelan, T. P. M.
    Dilling, D. F.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [30] Post-Hospitalization Mortality in Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry
    Kim, H.
    Snyder, L. D.
    Adegunsoye, A.
    Neely, M. L.
    Bender, S.
    White, E. S.
    Conoscenti, C. S.
    Strek, M. E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)